Response of iron overload to deferasirox in rare transfusion-dependent anaemias: Equivalent effects on serum ferritin and labile plasma iron for haemolytic or production anaemias

European Journal of Haematology

Volumn 87, Issue 4, 2011, Pages 338-348

  Porter, John B ^a   Lin, Kai Hsin ^b   Beris, Photis ^c,h   Forni, Gian Luca ^d   Taher, Ali ^e   Habr, Dany ^f   Domokos, Gabor ^f   Roubert, Bernard ^f   Thein, Swee Lay ^g  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^d GALLIERA HOSPITAL   (Italy)

^e AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^f NOVARTIS PHARMA AG   (Switzerland)

^g KING'S COLLEGE LONDON   (United Kingdom)

^h Unilabs   (France)

Author keywords

Iron chelation therapy; Iron overload; Rare anaemias; Safety; Serum ferritin

Indexed keywords

CYCLOSPORIN; DEFERASIROX; DEFEROXAMINE; FERRITIN; IRON;

ABDOMINAL DISTENSION; ADOLESCENT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANGIONEUROTIC EDEMA; ARTICLE; CHELATION THERAPY; CHILD; CHOLELITHIASIS; CLINICAL TRIAL; CONSTIPATION; CREATININE BLOOD LEVEL; DIARRHEA; DIZZINESS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; ERYTHROCYTE TRANSFUSION; FATIGUE; FEMALE; FERRITIN BLOOD LEVEL; HEMOLYTIC ANEMIA; HUMAN; HYPERPYREXIA; IRON BLOOD LEVEL; IRON CHELATION; IRON OVERLOAD; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; OPEN STUDY; PATIENT COMPLIANCE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; PRURITUS; PURE RED CELL ANEMIA; RASH; REBOUND; SCHOOL CHILD; SIDE EFFECT; TRANSFUSION DEPENDENT ANEMIA; UPPER ABDOMINAL PAIN; VOMITING;

ADOLESCENT; ANEMIA; BENZOIC ACIDS; BLOOD TRANSFUSION; CHILD; CHILD, PRESCHOOL; FEMALE; FERRITINS; HUMANS; IRON; IRON CHELATING AGENTS; IRON OVERLOAD; MALE; TRIAZOLES;

EID: 80053222965     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2011.01660.x     Document Type: Article

References (33)

1. Kushner JP, Porter JP, Olivieri NF. Secondary iron overload. Hematology Am Soc Hematol Educ Program 2001;47-61. Accessed July 22, 2011.
2. Takatoku M, Uchiyama T, Okamoto S, et al. Retrospective nationwide survey of Japanese patients with transfusion-dependent MDS and aplastic anemia highlights the negative impact of iron overload on morbidity/mortality. Eur J Haematol 2007;78:487-94.
3. Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica 2004;89:1187-93.
4. Porter J, Galanello R, Saglio G, et al. Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study. Eur J Haematol 2008;80:168-76.
5. Cappellini MD, Porter JB, El-Beshlawy A, et al. Tailoring iron chelation by iron intake and serum ferritin trends: the prospective multicenter EPIC study of deferasirox in 1744 patients with various transfusion-dependent anemias. Haematologica 2010;95:557-66.
6. Park SJ, Han CW. Complete hematopoietic recovery after continuous iron chelation therapy in a patient with severe aplastic anemia with secondary hemochromatosis. J Korean Med Sci 2008;23:320-3.
7. Vichinsky E, Onyekwere O, Porter J, et al. A randomized comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. Br J Haematol 2007;136:501-8.
8. Gattermann N, Finelli C, Della Porta M, et al. Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study. Leuk Res 2010;34:1143-50.
9. Cohen AR, Glimm E, Porter JB. Effect of transfusional iron intake on response to chelation therapy in β-thalassemia major. Blood 2008;111:583-7.
10. Esposito BP, Breuer W, Sirankapracha P, Pootrakul P, Hershko C, Cabantchik ZI. Labile plasma iron in iron overload: redox activity and susceptibility to chelation. Blood 2003;102:2670-7.
11. 2+ channels provide a major pathway for iron entry into cardiomyocytes in iron-overload cardiomyopathy. Nat Med 2003;9:1187-94.
12. Liuzzi JP, Aydemir F, Nam H, Knutson MD, Cousins RJ. Zip14 (Slc39a14) mediates non-transferrin-bound iron uptake into cells. Proc Natl Acad Sci USA 2006;103:13612-7.
13. Porter J. Pathophysiology of iron overload. Hematol Oncol Clin North Am 2005;19(Suppl 1):7-12.
14. Porter JB, Abeysinghe RD, Marshall L, Hider RC, Singh S. Kinetics of removal and reappearance of non-transferrin-bound plasma iron with deferoxamine therapy. Blood 1996;88:705-13.
15. Pootrakul P, Breuer W, Sametband M, Sirankapracha P, Hershko C, Cabantchik ZI. Labile plasma iron (LPI) as an indicator of chelatable plasma redox activity in iron-overloaded β-thalassemia/HbE patients treated with an oral chelator. Blood 2004;104:1504-10.
16. Wickramasinghe SN, Thein SL, Srichairatanakool S, Porter JB. Determinants of iron status and bilirubin levels in congenital dyserythropoietic anaemia type 1. Br J Haematol 1999;107:522-5.
17. 12 treatment. Hematol J 2004;5:32-4.
18. Bradley SJ, Gosriwitana I, Srichairatanakool S, Hider RC, Porter JB. Non-transferrin-bound iron induced by myeloablative chemotherapy. Br J Haematol 1997;99:337-43.
19. Lee J-W, Yoon S-S, Shen ZX, Ganser A, Hsu H-C, Habr D, Domokos G, Roubert B, Porter JB. Iron chelation therapy with deferasirox in patients with aplastic anemia: a subgroup analysis of 116 patients from the EPIC trial. Blood 2010;116:2448-54.
20. Olivieri NF, Nathan DG, MacMillan JH, Wayne AS, Liu PP, McGee A, Martin M, Koren G, Cohen AR. Survival in medically treated patients with homozygous β-thalassemia. N Engl J Med 1994;331:574-8.
21. Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. Blood 1997;89:739-61.
22. Cabantchik ZI, Breuer W, Zanninelli G, Cianciulli P. LPI-labile plasma iron in iron overload. Best Pract Res Clin Haematol 2005;18:277-87.
23. Roggero S, Quarello P, Vinciguerra T, Longo F, Piga A, Ramenghi U. Severe iron overload in Blackfan-Diamond anemia: a case-control study. Am J Hematol 2009;84:729-32.
24. Worwood M, Cragg SJ, Jacobs A, McLaren C, Ricketts C, Economidou J. Binding of serum ferritin to concanavalin A: patients with homozygous beta thalassaemia and transfusional iron overload. Br J Haematol 1980;46:409-16.
25. Daar S, Pathare A, Nick H, Kriemler-Krahn U, Hmissi A, Habr D, Taher A. Reduction in labile plasma iron during treatment with deferasirox, a once-daily oral iron chelator, in heavily iron-overloaded patients with β-thalassaemia. Eur J Haematol 2009;82:454-7.
26. ®) improves iron burden in patients with myelodysplastic syndromes (MDS). Blood 2008;112:abst 634.
27. ®) therapy in a cohort of patients with MDS. Leuk Res 2009;33(Suppl 1):S120 (abst P104).
28. Ghoti H, Fibach E, Merkel D, Perez-Avraham G, Grisariu S, Rachmilewitz EA. Changes in parameters of oxidative stress and free iron biomarkers during treatment with deferasirox in iron-overloaded patients with myelodysplastic syndromes. Haematologica 2010;95:1433-4.
29. Jensen PD, Jensen FT, Christensen T, Eiskjaer H, Baandrup U, Nielsen JL. Evaluation of myocardial iron by magnetic resonance imaging during iron chelation therapy with deferrioxamine: indication of close relation between myocardial iron content and chelatable iron pool. Blood 2003;101:4632-9.
30. ®) on labile plasma iron levels in heavily iron-overloaded patients with transfusion-dependent anemias enrolled in the large-scale, prospective 1-year EPIC trial. Blood 2008;112:abst 3881.
31. Cappellini MD, Cohen A, Piga A, et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with β-thalassemia. Blood 2006;107:3455-62.
32. ® (deferasirox) US Prescribing Information. 2010. Available at: .
33. Burdmann EA, Andoh TF, Yu L, Bennett WM. Cyclosporine nephrotoxicity. Semin Nephrol 2003;23:465-76.